Avenue Therapeutics (ATXI) Misses Q1 EPS by 640c

Avenue Therapeutics (NASDAQ: ATXI) reported Q1 EPS of ($15.40), $6.40 worse than the analyst estimate of ($9.00).

For earnings history and earnings-related data on Avenue Therapeutics (ATXI) click here.

You May Also Be Interested In

• Tesla to launch Cybercab in Austin this month - report
• Duos Technologies Group, Inc. (DUOT) Tops Q2 EPS by 163c
• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance